SonoThera
Develops ultrasound-mediated nonviral genetic medicines
$125MSeries B
Role not disclosedVC
Vivo Capital
Activity from announced rounds
Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $335M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionKinaset Therapeutics
Develops inhaled therapies for severe respiratory diseases
$103MSeries B
Role not disclosedEpiBiologics
Develops bispecific antibodies for targeted degradation of extracellular proteins.
$107MSeries B
Role not disclosed